

**592 RESPIRATORY DISBIOSIS IN THE CHILDREN WITH FIRST DIAGNOSED TUBERCULOSIS**

doi:10.1136/archdischild-2012-302724.0592

OM Horlenko, LY Markovtsiy. *Pediatrics and Infectious Diseases, Uzhgorod National University, Medical Faculty, Uzhgorod, Ukraine*

**Background and Aims** Second disbiosis of the respiratory play the presentative role and had negatively influence on the result of duration of infectious diseases and assists development of immune disbalance of mucous membranes of respiratory tract.

**Methods** We investigated 24 children with the First Diagnosed Pulmonary Tuberculosis (FDPT) in the age from 1–16 years. Research of microflora of respiratory tracts was conducted by a bacteriologic examination of native material (expectoration).

**Results** The inspected contingent had Pulmonary form of the first diagnosed tuberculosis. The patients concluded: child to 3 years - 50.00%. other 50.00% children contained the group of pubertat period. Distributing on the forms of tubercular process: primary tubercular complex - 25.00%, pulmonary focus tuberculose 12.50%, disseminated tuberculosis - 25.00%, infiltrative tuberculosis - 37.50%. 58.30% children had associatin pathology with the FDPT: anaemia in 25.00% cases, pneumonia - 8.30%, HIV - 8.30%. In microbiological culture was confirmed presence of *M. tuberculosis* in 33.30% cases. The destructive chang in lung 16.70% cases was identified. *N.sicca* was presented in 40.00% children with the normal microflora and *S.epidermidis* - in 60.00%. In 50.00% cases of children with the FDPT disbiosis violations was identified after the beginning of using of antiphthisic treatment. Disbiosis as a monoculture found in 83.3% cases, in 16.70% cases - as associations of cultures. In 33.30% cases found out *Escherichia coli*, in the 16.70% - *K.pneumonia*, in the 50.00% cases - *Candida A*.

**Conclusions** On the basis of the conducted researches are set presence of respiratory dysbiosis in children with the FDPT.

**593 PERSISTENTLY ELEVATED RIGHT VENTRICULAR INDEX OF MYOCARDIAL PERFORMANCE IN PRETERM INFANTS WITH INCIPENT BRONCHOPULMONARY DYSPLASIA**

doi:10.1136/archdischild-2012-302724.0593

C Czernik, S Rhode, B Metzke, G Schmalisch, C Buehrer. *Klinik für Neonatologie, Charité Universitätsmedizin Berlin, Berlin, Germany*

**Objectives** Elevated pulmonary vascular resistance occurs during the first days after birth in all newborn infants and persists in infants at risk for bronchopulmonary dysplasia (BPD). Pulmonary vascular resistance is higher during the first days after birth and in preterm infants with incipient bronchopulmonary dysplasia (BDP). It is difficult to measure in a non-invasive fashion. We assessed the usefulness of the right ventricular index of myocardial performance (RIMP) to estimate pulmonary vascular resistance in very low birth weight infants.

**Study Design** Prospective echocardiography on day of life (DOL) 2, 7, 14, and 28 in 121 preterm infants (median [quartiles] gestational age 28 [26–29] weeks, birth weight 998 [743–1225] g) of whom 36 developed BPD (oxygen supplementation at 36 postmenstrual weeks).

**Results** RIMP derived by conventional pulsed Doppler technique was unrelated to heart rate or mean blood pressure. RIMP on DOL 2 was similar in infants who subsequently did (0.39 [0.33–0.55]) and did not develop BPD (0.39 [0.28–0.51],  $p=0.467$ ). RIMP declined steadily in non-BPD infants but not in BPD infants (DOL 7: 0.31[0.22–0.39] vs. 0.35[0.29–0.48],  $p=0.014$ ; DOL 14: 0.23[0.17–0.30] vs. 0.35[0.25–0.43],  $p<0.001$ ; DOL 28: 0.21[0.15–0.28] vs. 0.31 [0.21–0.35],  $p=0.015$ ).

**Conclusions** In preterm infants, a decline in RIMP after birth was not observed in those with incipient BPD. The pattern of RIMP

measured in preterm infants is commensurate with that of pulmonary vascular resistance.

**594 A NEONATAL RAT MODEL OF BRONCHOPULMONARY DYSPLASIA INDUCED BY PRE- AND POSTNATAL INFLAMMATION WITHOUT EXPOSURE TO HYPEROXIA**

doi:10.1136/archdischild-2012-302724.0594

<sup>1,2</sup>CW Choi, <sup>1,3</sup>HJ Lee, <sup>1</sup>YJ Lee, <sup>1,2</sup>JM Lee, <sup>2</sup>JA Lee, <sup>2</sup>EK Kim, <sup>2</sup>HS Kim, <sup>1,2</sup>BI Kim, <sup>2</sup>JH Choi. <sup>1</sup>Medical Research Institute, Seoul National University Bundang Hospital, Seongnam; <sup>2</sup>Department of Pediatrics, Seoul National University College of Medicine; <sup>3</sup>Department of Pediatrics, Hanyang University Hospital, Seoul, Republic of Korea

**Purpose** We tested if pre- or postnatal inflammation can develop BPD per se and if there are any interaction between prenatal and postnatal inflammation.

**Methods** Two days before delivery (E20), 1 µg of lipopolysaccharide (LPS) or vehicle (V) was injected into each amniotic sac, and after birth 0.25 mg/kg of LPS or vehicle was injected into peritoneum on P1, P3, and P5. This led to four experimental groups. On P7 and P14, their lungs and hearts were harvested, and alveolarization and lung vascular density were evaluated.

**Results** Morphometric analysis of P7 lungs revealed that both preLPS+postLPS group and V+postLPS group had significantly larger and less complex airspaces and small alveolar surface area than V+V group. On P14, only V+postLPS group had significantly larger and less complex airspaces than V+V group. However, alveolar surface areas were significantly smaller both in preLPS+postLPS group and V+postLPS group than in V+V group. Lung vascular density of both preLPS+postLPS group and V+postLPS group was significantly lesser than V+V group.

**Conclusions** At these intra-amniotic and postnatal systemic LPS doses, prenatal intra-amniotic LPS injection per se did not affect postnatal alveolar and pulmonary vascular development, while postnatal systemic LPS injection significantly inhibited alveolar and pulmonary vascular development regardless of whether prenatal intra-amniotic LPS was injected or not. There was no definite interaction between intra-amniotic LPS and postnatal systemic LPS on the lung development. This rat model of BPD could be used as a valuable tool for testing the effect of anti-inflammatory agents on the prevention of BPD.

**595 RISK FACTORS FOR BRONCHO-PULMONARY DYSPLASIA IN VERY-LOW-GESTATIONAL-AGE INFANTS**

doi:10.1136/archdischild-2012-302724.0595

<sup>1</sup>A Valls-i-Soler, <sup>2</sup>A Azpeitia, <sup>3</sup>H Hummler, <sup>4</sup>H Halliday, European Neonatal Network (EuroNeoNet). <sup>1</sup>Cruces University Hospital; <sup>2</sup>BIOEF, Barakaldo, Spain; <sup>3</sup>Pediatrics and Adolescent Medicine University Hospital, Ulm, Germany; <sup>4</sup>Institute Clinical Science, Belfast, UK

**Background** BPD is a severe condition that has decreased in severity but remains a major long-term adverse outcome of surviving Very Low Gestational Age (VLGA) infants.

**Aim** To determine the BPD rate and evaluate its predictive and associated factors.

**Methods** BPP (need for supplemental O<sub>2</sub> at 36 wks CGA) rate and associated risk factors were analysed in a cohort of 24,087 VLGA infants admitted from 2006 to 2010 to 174 EuroNeoNet NICUs. Non-parametric independent tests and logistic regression models were performed to predict BPD, using crude and adjusted odd ratios (OR) to determine perinatal and early neonatal associations. Predictive capacity was assessed by Hosmer-Lemeshow test and discrimination by area under ROC curve (AUC).

**Results** BPD was diagnosed in 16% (95%CI: (15.4%–16.1%)) of infants, who had significantly lower GA, BW and Apgar scores. They were more frequently male, from single pregnancies, more often had



## 592 Respiratory Disbioses in the Children with First Diagnosed Tuberculosis

OM Horlenko and LY Markovtsiy

*Arch Dis Child* 2012 97: A172

doi: 10.1136/archdischild-2012-302724.0592

---

Updated information and services can be found at:

[http://adc.bmj.com/content/97/Suppl\\_2/A172.1](http://adc.bmj.com/content/97/Suppl_2/A172.1)

---

*These include:*

**Email alerting  
service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

**Notes**

---

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>